1 |
Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 [J]. Cancer Commun (Lond), 2021, 41(10): 1037-1048.
|
2 |
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J]. N Engl J Med, 2004, 351(15): 1502-1512.
|
3 |
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer [J]. N Engl J Med, 2011, 364(21): 1995-2005.
|
4 |
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy [J]. N Engl J Med, 2013, 368(2): 138-148.
|
5 |
Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial [J]. Lancet Oncol, 2014, 15(10): 1147-1156.
|
6 |
Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study [J]. Eur Urol, 2017, 71(2): 151-154.
|
7 |
Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial [J]. Lancet Oncol, 2014, 15(12): 1397-1406.
|
8 |
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J]. Lancet, 2016, 387(10024): 1163-1177.
|
9 |
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer [J]. N Engl J Med, 2015, 373(8): 737-746.
|
10 |
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer [J]. N Engl J Med, 2017, 377(4): 352-360.
|
11 |
James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy [J]. N Engl J Med, 2017, 377(4): 338-351.
|
12 |
Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer [J]. N Engl J Med, 2019, 381(2): 121-131.
|
13 |
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer [J]. J Clin Oncol, 2019, 37(32): 2974-2986.
|
14 |
Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer [J]. N Engl J Med, 2019, 381(1): 13-24.
|
15 |
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer [J]. N Engl J Med, 2022, 386(12): 1132-1142.
|
16 |
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group [J]. J Clin Oncol, 2008, 26(7): 1148-1159.
|
17 |
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 [J]. J Clin Oncol, 2016, 34(12): 1402-1418.
|
18 |
Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making [J]. JCO Precis Oncol, 2017, 2017.
|
19 |
Flaig TW, Barqawi A, Miller G, et al. A phase Ⅱ trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer [J]. Cancer, 2006, 107(2): 266-274.
|
20 |
Oh WK, Halabi S, Kelly WK, et al. A phase Ⅱ study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813 [J]. Cancer, 2003, 98(12): 2592-2598.
|
21 |
Bouman-Wammes EW, van den Berg HP, de Munck L, et al. A randomised phase Ⅱ trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial [J]. Eur J Cancer, 2018, 90: 1-9.
|
22 |
Vaishampayan U, Shevrin D, Stein M, et al. Phase Ⅱ trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer clinical trial consortium study [J]. Urology, 2015, 86(6): 1206-1211.
|
23 |
Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer [J]. N Engl J Med, 2015, 373(18): 1697-1708.
|
24 |
Leal F, García-Perdomo HA. Effectiveness of platinum-based chemotherapy in patients with metastatic prostate cancer: systematic review and meta-analysis [J]. Clin Genitourin Cancer, 2019, 17(3): e627-e644.
|